Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AH23844 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| AH23844 (lavoltidine) | DRUG | - |
| NEXIUM (esomeprazole) | DRUG | - |
| ZANTAC (ranitidine) | DRUG | - |
Inclusion criteria: * Subject must have a Body Mass Index (BMI) from 19-30 kg/m2 * Subject does not present with abnormal clinical lab findings * Subject is able to tolerate a nasogastric pH electrode. Exclusion criteria: * Subject is Helicobacter-positive on a C13 urea breath test * Subject has ...
AH23844 is an investigational small molecule being studied for the treatment of Gastroesophageal Reflux Disease (GERD). It is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
AH23844 is being developed by GSK plc, a pharmaceutical company listed on the stock exchange under the ticker symbol GSK. The drug is in Phase 2 clinical trials for Gastroesophageal Reflux Disease.
AH23844 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved for commercial use. The drug is being studied for the treatment of Gastroesophageal Reflux Disease.
AH23844 has one completed Phase 2 clinical trial with the identifier NCT00405119. This study investigated the effectiveness of AH234844 (Lavoltidine) compared with NEXIUM and ranitidine in patients with Gastroesophageal Reflux Disease. The trial enrolled 92 participants in Australia.
Yes, AH23844 is also known as Lavoltidine. In clinical trial NCT00405119, the drug is referred to as AH234844 (Lavoltidine), indicating that AH23844 and Lavoltidine are alternative names for the same investigational drug.